Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 37Lymphoma, Follicular 22Lymphoma, Mantle-Cell 18Lymphoma, Large B-Cell, Diffuse 14Lymphoma, B-Cell, Marginal Zone 11Lymphoma, Non-Hodgkin 10Lymphoma 6Neoplasms 4Lymphoma, B-Cell 4Leukemia, B-Cell 3Leukemia 3Waldenstrom Macroglobulinemia 2Neoplasm, Residual 2Leukemia, Hairy Cell 2Dendritic Cell Sarcoma, Interdigitating 2Recurrence 1Oncology Patients Receiving Chemotherapy 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Indolent Non-Hodgkin's Lymphoma 1Indolent Non-Hodgkin Lymphoma 1Disease 1Cytokine Release Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 46fludarabine phosphate 24Busulfan 22Peripheral Blood Stem Cell Transplantation 20Radiotherapy 19Filgrastim 19Mycophenolic Acid 18Antilymphocyte Serum 18Cyclosporine 17Whole-Body Irradiation 16Rituximab 16Etoposide 16Methotrexate 15Melphalan 15Methylprednisolone 14Tacrolimus 12Cytarabine 12Vincristine 10Prednisone 10Doxorubicin 10Cord Blood Stem Cell Transplantation 10Thiotepa 6Granulocyte Colony-Stimulating Factor 6Leucovorin 5sargramostim 4fludarabine 4Daunorubicin 4glofitamab 3Sirolimus 3Methylprednisolone Hemisuccinate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Dendritic Cell Sarcoma, Interdigitating × obinutuzumab × Clear all
NCT04889716 2026-05-26

CAR-T Followed by Bispecific Antibodies

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
23 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07326371 2026-01-08

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

Ruijin Hospital

Phase 2 Not yet recruiting
24 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡